Update on Current Care Guideline: Multiple sclerosis
Remes, A.; Airas, L.; Atula, S.; Färkkilä, M.; Hartikainen, Päivi.; Koivisto, K.; Mäenpää, E.; Ruutiainen, J.; Sumelahti, M-Liisa.
Duodecim; Laaketieteellinen Aikakauskirja 131(5): 500-501
2015
ISSN/ISBN: 0012-7183 PMID: 26237913 Document Number: 680894
Treatment for relapsing-remitting multiple sclerosis (RRMS) is initiated upon fulfillment of new McDonald 2010 criteria for RRMS. In addition, lumbar puncture is an essential diagnostic method. Interferon-β, dimethyl fumarate, glatiramer acetate and teriflunomide are the first-line immunomodulating drugs (IMD) for RRMS. If the disease is active according to clinical or MRI evaluation during the first-line IMD treatment, alemtuzumab, fingolimod or natalizumab may be considered as second-line therapies. IMD treatment is discontinued upon the transition of RRMS to secondary progressive phase. Rehabilitation should be considered at every phase of the disease.